[1]都 燕,代 佳.血清细胞角蛋白19片段、α-烯醇化酶检测在子宫内膜癌诊断及病情严重程度评估中的价值[J].陕西医学杂志,2023,52(2):212-216.[doi:DOI:10.3969/j.issn.1000-7377.2023.02.022]
　DU Yan,DAI Jia.Value of serum cytokeratin 19 fragment and α-enolase detection in diagnosis and severity assessment of endometrial carcinoma[J].,2023,52(2):212-216.[doi:DOI:10.3969/j.issn.1000-7377.2023.02.022]
点击复制

血清细胞角蛋白19片段、α-烯醇化酶检测在子宫内膜癌诊断及病情严重程度评估中的价值
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
52
期数:
2023年2期
页码:
212-216
栏目:
临床检验
出版日期:
2023-02-05

文章信息/Info

Title:
Value of serum cytokeratin 19 fragment and α-enolase detection in diagnosis and severity assessment of endometrial carcinoma
作者:
都 燕1; 代 佳2
(1.延安大学附属医院,陕西 延安 716000; 2.陕西省肿瘤医院,陕西 西安 710061)
Author(s):
DU Yan; DAI Jia
(Affiliated Hospital of Yan'an University,Yan'an 716000,China)
关键词:
子宫内膜癌;  细胞角蛋白19片段;  α-烯醇化酶;  病理特征;  诊断;  病情评估
Keywords:
Endometrial carcinoma;  Cytokeratin 19 fragment;  Alpha-enolase;  Pathological features;  Diagnosis;  Condition evaluation
分类号:
R 737.33
DOI:
DOI:10.3969/j.issn.1000-7377.2023.02.022
文献标志码:
A
摘要:
目的:探讨血清细胞角蛋白19片段(CYFRA21-1)、α-烯醇化酶(ENO1)检测对子宫内膜癌的诊断价值以及对患者病情严重程度的评估作用。方法:选择83例子宫内膜癌患者、95例良性子宫内膜疾病患者和100例健康女性作为研究对象。采用酶联免疫吸附法检测血清CYFRA21-1、ENO1水平,比较各组血清CYFRA21-1、ENO1水平差异。分析血清CYFRA21-1、ENO1水平与子宫内膜癌患者病理特征的关系。采用受试者工作特征(ROC)曲线分析血清CYFRA21-1、ENO1水平诊断子宫内膜癌的效能。结果:子宫内膜癌组血清CYFRA21-1、ENO1水平高于良性子宫内膜疾病组和对照组,良性子宫内膜疾病组血清CYFRA21-1、ENO1水平高于对照组(均P<0.05)。透明细胞癌患者血清CYFRA21-1、ENO1水平高于其他三种类型,鳞癌患者血清CYFRA21-1、ENO1水平高于腺癌和混合性癌(均P<0.05)。Ⅲ期和Ⅳ期患者血清CYFRA21-1、ENO1水平均高于Ⅰ期和Ⅱ期患者(均P<0.05); Ⅱ期患者血清CYFRA21-1、ENO1水平高于Ⅰ期患者(均P<0.05)。不同分化程度患者血清CYFRA21-1、ENO1水平两两比较均有统计学差异(均P<0.05),高分化患者血清CYFRA21-1、ENO1水平最高。肌层浸润≥1/2、发生淋巴结转移的患者血清CYFRA21-1、ENO1水平高于肌层浸润<1/2、未发生淋巴结转移的患者(P<0.05)。复发组和术后1年内死亡的子宫内膜癌患者血清CYFRA21-1、ENO1水平均高于未复发组和未死亡患者(均P<0.05)。血清CYFRA21-1诊断子宫内膜癌的AUC为0.939,以≥4.8 ng/ml作为诊断阈值,其敏感度、特异度和约登指数分别为95.18%、75.90%和71.08%; 血清ENO1诊断子宫内膜癌的AUC为0.879,以≥482.5 pg/ml作为诊断阈值,其敏感度、特异度和约登指数分别为85.54%、76.92%和62.47%。结论:血清CYFRA21-1、ENO1水平提高与子宫内膜癌多种病理特征相关,术后复发和1年内死亡患者血清CYFRA21-1、ENO1水平增加尤为明显,通过检测这两个指标可辅助诊断子宫内膜癌并对病情进行评估。
Abstract:
Objective:To investigate the diagnostic value of serum cytokeratin 19 fragment(CYFRA21-1)and alpha-enolase(ENO1)detection in endometrial carcinoma and their roles in evaluating the severity of patients' condition.Methods:A total of 83 patients with endometrial carcinoma,95 patients with benign endometrial disease and 100 healthy women were selected as the subjects.The levels of serum CYFRA21-1 and ENO1 were detected by enzyme-linked immunosorbent assay,and the differences of serum CYFRA21-1 and ENO1 levels among the groups were compared.The relationship between serum CYFRA21-1,ENO1 levels and pathological characteristics of endometrial cancer patients was analyzed.ROC curve was used to analyze the efficacy of serum CYFRA21-1 and ENO1 levels in the diagnosis of endometrial carcinoma.Results:The levels of serum CYFRA21-1 and ENO1 in endometrial carcinoma group were significantly higher than those in benign endometrial disease group and control group,and the levels of serum CYFRA21-1 and ENO1 in benign endometrial disease group were higher than those in control group(all P<0.05).The levels of serum CYFRA21-1 and ENO1 in patients with clear cell carcinoma were higher than those of the other three types,and the levels of serum CYFRA21-1 and ENO1 in patients with squamous cell carcinoma were higher than those of adenocarcinoma and mixed carcinoma(all P<0.05).The levels of serum CYFRA21-1 and ENO1 in patients with stage Ⅲ and Ⅳ were higher than those in patients with stage Ⅰ and Ⅱ,and the levels of serum CYFRA21-1 and ENO1 in patients with stage Ⅱ were higher than those in patients with stage Ⅰ(all P<0.05).The levels of serum CYFRA21-1 and ENO1 in patients with different degrees of differentiation were different(all P<0.05),and the levels of serum CYFRA21-1 and ENO1 in patients with high differentiation were the highest.The serum CYFRA21-1 and ENO1 levels in patients with myometrial invasion ≥1/2 and lymph node metastasis were higher than those in patients with myometrial invasion <1/2 and no lymph node metastasis(all P<0.05).The serum levels of CYFRA21-1 and ENO1 in the recurrent group and dead patients within one year were higher than those in the non-recurrent group and the non-dead patients,respectively(all P<0.05).The AUC of serum CYFRA21-1 in the diagnosis of endometrial carcinoma was 0.939,taking ≥4.8 ng/ml as the diagnostic threshold,its sensitivity,specificity and Youden index were 95.18%,75.90% and 71.08% respectively.The AUC of serum ENO1 in the diagnosis of endometrial carcinoma was 0.879,taking ≥482.5 pg/ml as the diagnostic threshold,its sensitivity,specificity and Youden index were 85.54%,76.92% and 62.47% respectively.Conclusion:The increase of serum CYFRA21-1 and ENO1 levels is related to a variety of pathological characteristics of endometrial carcinoma.The increase of serum CYFRA21-1 and ENO1 levels is particularly obvious in patients with postoperative recurrence and death within one year.The detection of these two indicators can assist in the diagnosis of endometrial carcinoma and the evaluation of the condition.

参考文献/References:

[1] Zhang S,Sun K,Zheng R,et al.Cancer incidence and mortality in China,2015[J].Journal of the National Cancer Center,2021,121(1):2-11.
[2] 张晓勇.宫腔镜辅助下分段诊刮术与单纯分段诊刮术诊断子宫内膜癌价值比较[J].陕西医学杂志,2019,48(8):1045-1048.
[3] 高 歌.黄芪注射液治疗子宫内膜肿瘤临床疗效及对患者肿瘤标志物血清CA125、HE4影响的研究[J].陕西中医,2018,39(6):762-765.
[4] 陈洈伟,徐 丹,王 艳,等.血清HE4、NGAL和CA125联合检测对子宫内膜癌的临床诊断意义[J].陕西医学杂志,2018,47(11):1500-1502.
[5] Am A,Ns B,Hs B,et al.Differential expression profiling of transcripts of IDH1,CEA,Cyfra21-1,and TPA in stage IIIa non-small cell lung cancer(NSCLC)of smokers and non-smokers cases with air quality index[J].Gene,2020,766:145151.
[6] 李汝芳,刘 凌,王旭明,等.α-烯醇化酶在恶性胸腔积液诊断中的应用研究[J].中国全科医学,2017,20(14):1689-1692.
[7] 智明春,孙 亮,李 炜,等.超声宫腔异常老年女性中血清肿瘤标志物对子宫内膜癌诊断意义[J].中华老年医学杂志,2019,38(1):47-49.
[8] 李 琰,慕珂珂,董炎红,等.CEA、CA19-9、CA125、HE4与绝经期ROMA值测定对子宫内膜癌临床分期的价值研究[J].国际检验医学杂志,2019,40(3):304-307.
[9] 杨学兰,高 岭.血清人附睾蛋白4、 CA199、 CEA单项及联合检测对子宫内膜癌的诊断价值研究[J].中国药物与临床,2018,18(8):1399-1401.
[10] Paz DD,Young CK,Chien HT,et al.Prognostic roles of SCC antigen,CRP and CYFRA 21-1 in oral cavity squamous cell carcinoma[J].Anticancer Research,2019,39(4):2025-2033.
[11] 杜春然,王彦明,侯申岩,等.CYFRA21-1、CA19-9和SCCAg检测在食管癌诊断中的价值研究[J].癌症进展,2018,16(2):186-188.
[12] 高 洁,张伦军,彭 珂,等.血清肿瘤标志物CEA、CYFRA21-1、SCCAg、NSE、ProGRP在不同病理分型肺癌诊断中的应用价值[J].南方医科大学学报,2022,42(6):886-891.
[13] Svaton M,Blazek J,Krakorova G,et al.Prognostic role for CYFRA 21-1 in patients with advanced-stage NSCLC treated with bevacizumab plus chemotherapy[J].Anticancer Research,2021,41(4):2053-2058.
[14] Deyuan A,Chunlan G,Jinli D,et al.PGK1 is a potential survival biomarker and invasion promoter by regulating the HIF-1α-mediated epithelial-mesenchymal transition process in breast cancer[J].Cellular Physiology and Biochemistry:International Journal of Experimental Cellular Physiology,Biochemistry,and Pharmacology,2018,51:2434-2444.
[15] Cappello P,Principe M,Bulfamante S,et al.Alpha-enolase(ENO1):A potential target in novelimmunotherapies[J].Front Biosci(Landmark Ed),2017,22(1):944-959.
[16] Cappello P,Curcio C,Mandili G,et al.Next generation immunotherapy for pancreatic cancer:DNA vaccination is seeking new combo partners[J].Cancers(Basel),2018,10(2):51-70.
[17] 张丽敏,王怡悦,钟慧欲.超声弹性成像联合血清ENO1抗体对乳腺癌的诊断价值[J].中国卫生检验杂志,2022,32(2):209-211.
[18] 闫婷婷,马丽娜,唐媛媛,等.ENO1在肝癌细胞株和肝细胞癌中的表达及与临床病理参数的关系[J].宁夏医科大学学报,2017,39(7):768-772.
[19] 舒 雄,刘辉琦,潘韵芝,等.ENO1在胃癌干细胞中表达及其与胃癌侵袭转移的相关性研究[J].中国肿瘤,2019,21(2):143-149.
[20] 王亚玲.子宫内膜癌患者外周血HMGA1,CK19和CK20水平分析[J].中国生育健康杂志,2021,32(6):574-577.

相似文献/References:

[1]冯苗苗,曹秋雨.miR335在子宫内膜癌患者血清中的表达及检测临床意义[J].陕西医学杂志,2019,(2):252.
　FENG Miaomiao,CAO Qiuyu..The expression and significance of miR335 in serum of patients with endometrial carcinoma[J].,2019,(2):252.
[2]刘家利,谢小军.子宫内膜癌组织HIF-1α、血清CA125水平在患者病情与疾病预后评估中的价值[J].陕西医学杂志,2019,(6):800.
[3]张晓勇.宫腔镜辅助下分段诊刮术与单纯分段诊刮术诊断子宫内膜癌价值比较[J].陕西医学杂志,2019,(8):1045.
　ZHANG Xiaoyong..Comparison of hysteroscopy assisted dilatation and curettage and traditional dilatation  and curettage in the diagnosis of endometrial carcinoma[J].,2019,(2):1045.
[4]徐 珊,程 珂,刘鹏宇.子宫内膜癌组织血管紧张素(1-7)、miR-106b表达与患者临床病理分期相关性研究[J].陕西医学杂志,2022,51(5):621.[doi:DOI:10.3969/j.issn.1000-7377.2022.05.025]
　XU Shan,Cheng Ke,LIU Pengyu.Correlation between the expression of angiotensin(1-7),miR-106b in endometrial cancer tissue and clinicopathological stage of patients[J].,2022,51(2):621.[doi:DOI:10.3969/j.issn.1000-7377.2022.05.025]
[5]姚 田,马文娟.RP11-444D3.1与SOX5基因共表达激活cofilin/LIMK/Rac信号通路介导子宫内膜癌侵袭机制研究[J].陕西医学杂志,2023,52(4):390.[doi:DOI:10.3969/j.issn.1000-7377.2023.04.006]
　YAO Tian,MA Wenjuan.Co-expression of RP11-444D3.1 and SOX5 enhances endometrial cancer invasion by activating cofilin/LIMK/Rac pathway[J].,2023,52(2):390.[doi:DOI:10.3969/j.issn.1000-7377.2023.04.006]
[6]查善辉,刘 杰,任 洁,等.腹腔镜手术治疗老年子宫内膜癌疗效及对患者应激、疼痛和术后恢复的影响[J].陕西医学杂志,2023,52(5):536.[doi:DOI:10.3969/j.issn.1000-7377.2023.05.009]
　ZHA Shanhui,LIU Jie,REN Jie,et al.Clinical effect of laparoscopic surgery in treatment of elderly endometrial cancer and its influence on patients' stress,pain and postoperative recovery[J].,2023,52(2):536.[doi:DOI:10.3969/j.issn.1000-7377.2023.05.009]
[7]冯一平,袁浩鑫,曾尚云,等.肿瘤坏死因子受体相关因子6高表达对子宫内膜癌细胞侵袭、迁移及上皮间质转化的影响[J].陕西医学杂志,2023,52(11):1598.[doi:DOI:10.3969/j.issn.1000-7377.2023.11.032]
　FENG Yiping,YUAN Haoxin,ZENG Shangyun,et al.Effects of high expression of TRAF6 on invasion,migration and epithelial-mesenchymal transition of endometrial cancer cells[J].,2023,52(2):1598.[doi:DOI:10.3969/j.issn.1000-7377.2023.11.032]
[8]孔维娜,李 佳,赵淑华,等.代谢综合征在子宫内膜癌及其肿瘤微环境中的研究进展[J].陕西医学杂志,2023,52(11):1607.[doi:DOI:10.3969/j.issn.1000-7377.2023.11.034]
　KONG Weina,LI Jia,ZHAO Shuhua,et al.Progress of metabolic syndrome in endometrial cancer and its tumor microenvironment[J].,2023,52(2):1607.[doi:DOI:10.3969/j.issn.1000-7377.2023.11.034]
[9]左学骞,赵海波,李 丹.三结构域蛋白8、Ras相关蛋白35、多聚ADP核糖聚合酶1在子宫内膜癌组织中的表达及检测临床意义[J].陕西医学杂志,2024,(2):266.[doi:DOI:10.3969/j.issn.1000-7377.2024.02.026]
[10]周 琴,黄丽琼,胡丽蓉,等.超声造影参数评估子宫内膜癌患者预后价值研究[J].陕西医学杂志,2024,(8):1055.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.010]
　ZHOU Qin,HUANG Liqiong,HU Lirong,et al.Value of contrast-enhanced ultrasound parameters in evaluating prognosis of patients with endometrial carcinoma[J].,2024,(2):1055.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.010]

备注/Memo

备注/Memo:
基金项目:陕西省中医药管理局科研项目(2021-ZZ-LC023)
更新日期/Last Update: 2023-02-06